Possis Aims To Reverse AngioJet Losses With JETSTENT Trial
This article was originally published in The Gray Sheet
Executive Summary
Possis views its upcoming 500-patient JETSTENT trial as the final step in a three-part plan to overcome the damaging results of its 2004 AiMI study and recover lostAngioJet thrombectomy system sales
You may also be interested in...
Candela Sees Beaming Future In Family Practice As Stock Jumps 54%
Candela's improved access to the emerging family practice aesthetic market through an exclusive distribution deal with McKesson sparked investor interest in the aesthetic laser firm in November
Candela Sees Beaming Future In Family Practice As Stock Jumps 54%
Candela's improved access to the emerging family practice aesthetic market through an exclusive distribution deal with McKesson sparked investor interest in the aesthetic laser firm in November
Hologic’s Stock Up 20% On Mammography Study Results; OTC Index Flat
Medical imaging systems maker Hologic's shares surged nearly 14% to $53.44 on Sept. 16 after the New England Journal of Medicine posted study results showing that digital mammography has superior diagnostic accuracy than film in a subset of women